Cadwalader allows sharing content.
Email to a friend or colleague:
From
To
Subject
Email On January 30, 2013, in United States ex rel. v. Bristol Myers Squibb Company & Sanofi-Aventis U.S., LLC et al., Civ. No. 11-00246 (S.D. Ill.) ("BMS & Sanofi-Aventis"), the Court denied a motion to dismiss the relator's second amended False Claims Act ("FCA"), 31 U.S.C. § 3729 et seq. complaint alleging the defendants made false efficacy claims regarding Plavix, even though the United States Food and Drug Administration ("FDA") approved Plavix for the promoted uses. https://www.cadwalader.com/resources/clients-friends-memos/federal-court-finds-that-fda-drug-approval-is-not-complete-defense-to-false-claims-act-allegation-involving-on-label-promotion